Insider’s View: Deciphering Bluebird bio Inc (BLUE)’s Financial Health Through Ratios

In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The price of Bluebird bio Inc (NASDAQ: BLUE) closed at $0.92 in the last session, up 0.98% from day before closing price of $0.91. In other words, the price has increased by $0.98 from its previous closing price. On the day, 3.07 million shares were traded. BLUE stock price reached its highest trading level at $0.931 during the session, while it also had its lowest trading level at $0.9013.


We take a closer look at BLUE’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.42 and its Current Ratio is at 1.55. In the meantime, Its Debt-to-Equity ratio is 1.36 whereas as Long-Term Debt/Eq ratio is at 1.04.

On December 08, 2023, Morgan Stanley Upgraded its rating to Equal-Weight which previously was Underweight and also upped its target price recommendation from $3 to $7.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 03 ’24 when Klima Thomas J sold 3,834 shares for $0.97 per share. The transaction valued at 3,726 led to the insider holds 121,006 shares of the business.

Obenshain Andrew sold 6,095 shares of BLUE for $9,311 on Mar 04 ’24. The President and CEO now owns 279,998 shares after completing the transaction at $1.53 per share. On Mar 04 ’24, another insider, Klima Thomas J, who serves as the insider of the company, sold 4,573 shares for $1.53 each. As a result, the insider received 6,986 and left with 124,840 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BLUE now has a Market Capitalization of 177958688 and an Enterprise Value of 230364128. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.19 while its Price-to-Book (P/B) ratio in mrq is 0.44. Its current Enterprise Value per Revenue stands at 10.603 whereas that against EBITDA is -1.748.

Stock Price History:

The Beta on a monthly basis for BLUE is 0.82, which has changed by -0.74655646 over the last 52 weeks, in comparison to a change of 0.26253593 over the same period for the S&P500. Over the past 52 weeks, BLUE has reached a high of $5.53, while it has fallen to a 52-week low of $0.85. The 50-Day Moving Average of the stock is -3.92%, while the 200-Day Moving Average is calculated to be -49.70%.

Shares Statistics:

According to the various share statistics, BLUE traded on average about 6.18M shares per day over the past 3-months and 6305930 shares per day over the past 10 days. A total of 192.74M shares are outstanding, with a floating share count of 189.84M. Insiders hold about 1.51% of the company’s shares, while institutions hold 54.91% stake in the company. Shares short for BLUE as of 1718323200 were 29475366 with a Short Ratio of 4.77, compared to 1715731200 on 31599109. Therefore, it implies a Short% of Shares Outstanding of 29475366 and a Short% of Float of 16.33.

Earnings Estimates

The stock of Bluebird bio Inc (BLUE) is currently being evaluated by 11.0 analysts who are actively contributing to its market rating.On average, analysts expect EPS of -$0.65 for the current quarter, with a high estimate of -$0.45 and a low estimate of -$0.98, while EPS last year was $0.38. The consensus estimate for the next quarter is -$0.46, with high estimates of -$0.29 and low estimates of -$0.69.

Analysts are recommending an EPS of between -$1.27 and -$2.26 for the fiscal current year, implying an average EPS of -$1.75. EPS for the following year is -$1.67, with 12.0 analysts recommending between -$0.95 and -$2.86.

Revenue Estimates

According to 10 analysts, the current quarter’s revenue is expected to be $10.37M. It ranges from a high estimate of $17M to a low estimate of $7.8M. As of the current estimate, Bluebird bio Inc’s year-ago sales were $62kFor the next quarter, 10 analysts are estimating revenue of $18.38M. There is a high estimate of $22M for the next quarter, whereas the lowest estimate is $12.76M.

A total of 13 analysts have provided revenue estimates for BLUE’s current fiscal year. The highest revenue estimate was $49M, while the lowest revenue estimate was $29M, resulting in an average revenue estimate of $35.3M. In the same quarter a year ago, actual revenue was $3.6MBased on 13 analysts’ estimates, the company’s revenue will be $119.89M in the next fiscal year. The high estimate is $167.5M and the low estimate is $78M.

Most Popular